Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

ieved to have superior anticoagulant effects compared to other targets such as thrombin. Portola believes betrixaban will offer several advantages over warfarin and the FXa inhibitors in development, including a long half-life to support once-daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment.

Portola has successfully completed a Phase 2 trial demonstrating betrixaban's proof of clinical concept and a favorable tolerability profile in preventing venous thromboembolism in patients undergoing knee replacement surgery. Later this year, Portola will initiate a Phase 2 clinical study in 500 patients comparing the safety and tolerability of betrixaban to warfarin, the only marketed chronic, oral anticoagulant for stroke prevention in patients with atrial fibrillation.

The other Phase 2 drug candidate is PRT060128, an antiplatelet agent that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit over clopidogrel and other antiplatelet agents in development through its immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola's clinical studies to date with the IV and oral formulations have shown that PRT060128 is well tolerated at high drug levels. Later this year, Portola will initiate a Phase 2 trial comparing the safety, tolerability and efficacy of the IV bolus followed by the oral formulation (60 days of therapy) of PRT060128 to clopidogrel in 800 patients undergoing elective percutaneous coronary interventions (PCI).

Expanding Early Stage Pipeline

Portola is developing a universal Factor Xa inhibitor antidote with the goal of neutralizing the effect of small molecule Factor Xa inhibitors in patients experiencing moderate or major ble
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... VERNE, Calif. , Oct. 22, 2014 /PRNewswire/ ... readiness products, has developed APLS ® Body ... that minimizes the spread of bacteria and virus ... APLS Body Guard Bio features a rugged, ... finished edges that create a leak-proof inner chamber ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on ... reported positive top-line clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes. The ... States under a U.S. Food and ...
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Dec. 12, 2011 /PRNewswire-iReach/ -- Reagent ... a common compliance concern driving Quality Control departments ... VerGo Pharma Research proves to be an innovative ... their business practices this month.  Harness ...
... Phase III clinical trial data presented today contribute ... Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in ... have deeper levels of response compared to those ... The findings from the ENEST (Evaluating Nilotinib Efficacy ...
Cached Medicine Technology:VerGo Integrates New Solution for Tracking Compliance Dates 2Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 2Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 3Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 4Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 5Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 6Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 7Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 8Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 9Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 10Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 11Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 12Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 13Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 14Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 15Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 16
(Date:10/22/2014)... Arbor, MI (PRWEB) October 22, 2014 ... of Schools of Allied Health Professions (ASAHP) Conference on ... Founder and CEO will participate in a panel discussion ... and Practice. , Isabel Healthcare provides a diagnostic decision ... in improving the diagnosis skills of students and clinical ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Beth Israel Deaconess Medical Center (BIDMC) have received funding ... their 2009 Creativity Awards program, which supports innovative ideas ... , The one-year awards were made to 10 ... the only institution in New England to be funded ...
... 14 All it takes is "a big chunk of change" ... employee spearheaded the effort to raise more than $1,000 ... that supports families of children with congenital heart defects or heart ... checking account, we can start to do things that we,ve wanted ...
... April 14 Intrinsic Therapeutics, Inc. announced today that ... anular prosthesis for use in reconstructing soft tissues of ... to distribute the Barricaid throughout the European Union and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090414/NE98588LOGO ...
... Major Parkinson,s Organization to Launch Web Site Exclusively ... N.Y., April 14 The American Parkinson Disease ... a re-designed Web site, www.youngparkinsons.org , created ... (PD), their family members, friends, and healthcare providers. ...
... patients got temporary reprieve from daily injections , , ... of stem cell transplantation using the patient,s own cells ... of 23 patients newly diagnosed with type 1 diabetes ... patient even managed to go four years without needing ...
... STEWARTVILLE, Minn., April 14 Rochester Medical Corporation (Nasdaq: ... close on Thursday, April 30, 2009. The Company will ... report. The call will begin at 4:00 p.m. central ... Thomson/CCBN and can be accessed at Rochester Medical,s website at ...
Cached Medicine News:Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:TAN's Efforts Produce 'Chunk of Change' for Children With Heart Defects 2Health News:Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis 2Health News:New Young Onset Parkinson's Disease Web Site Goes Live 2Health News:New Young Onset Parkinson's Disease Web Site Goes Live 3Health News:Stem Cells Buy Freedom From Insulin for Type 1 Diabetics 2Health News:Stem Cells Buy Freedom From Insulin for Type 1 Diabetics 3Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2
Advanced Lighting System with Multi-Lamp Design providing Surgeon Focus Control and Extended, Variable Depth of Field over greater working distances. High Intensity, Cool Beam Temperature...
... technology that precisely focuses a column ... surgical site. Patented prism based technology ... illumination, shadow control, heat management and ... PrismAlix Series is available in a ...
... SureFlex™ line of reusable and autoclavable Lithotripsy ... This revolutionary and patented termination method accepts ... In the unlikely event you do manage ... face absolutely prevents damage to your laser ...
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
Medicine Products: